# Bioequivalence Study of Budesonide From Ekmasonid 9 mg Extended Release FCT (Hikma Pharma, Egypt) Versus Uceris 9 mg Extended Release Tablets (Man. for: Salix Pharm., a Division of Valeant Pharm. LLC, USA, by: Cosmo S.P.A., Italy by License of Cosmo Tech. Ltd., Ireland, Product of France)

> **NCT04854538** · PHASE1 · COMPLETED · sponsor: **Genuine Research Center, Egypt** · enrollment: 30 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Ekmasonid
- **DRUG:** Uceris (first dose)
- **DRUG:** Uceris (second dose)

## Key facts

- **NCT ID:** NCT04854538
- **Lead sponsor:** Genuine Research Center, Egypt
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-17
- **Primary completion:** 2020-10-01
- **Final completion:** 2020-12-04
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-04-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04854538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04854538, "Bioequivalence Study of Budesonide From Ekmasonid 9 mg Extended Release FCT (Hikma Pharma, Egypt) Versus Uceris 9 mg Extended Release Tablets (Man. for: Salix Pharm., a Division of Valeant Pharm. LLC, USA, by: Cosmo S.P.A., Italy by License of Cosmo Tech. Ltd., Ireland, Product of France)". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT04854538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*